Figure 1.

Immunoreactive area (percentage of the total area measured) of β-amyloid (a) and tau (b) burden in three hippocampal regions. (a) the burden of β-amyloid significantly decreased in the ovocystatin-treated transgenic group within all analyzed regions of the hippocampus, (b) deposits of misfolded tau protein significantly decreased in both non-carrier and transgenic ovocystatin-treated groups within all analysed hippocampal regions. NCAR—non-carrier group, NCAR+ovCYS—ovocystatin-treated non-carrier group, APP/PS1—transgenic group, APP/PS1+ovCYS—ovocystatin-treated transgenic group. Statistical significance of treated ovCYS versus untreated groups was indicated as * at p < 0.05, ** at p < 0.01, and *** at p < 0.001 within the respective hippocampal region.